Vivek Ramaswamy bags option rights on Daiichi’s pipeline drugs; Achillion drops a lead program; Ziopharm creates new development company for China
→ No longer content to pick off 1 drug at a time for his growing stable of companies, Roivant chief Vivek Ramaswamy has struck a deal that gives him options on a slate of programs in development at Daiichi Sankyo. And he can use these new drugs to seed the pipelines of his future startups.
→ At a time high insulin prices have become a lightning rod issue in the US, Novartis is teaming up with China’s Gan & Lee to provide cheaper knockoffs of three big brands.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.